Skip to content

Author

F. Nardi

We have 10 of 71 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Nov 2026

Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide.

BACKGROUND Cardiovascular death (CVD) remains a leading cause of global mortality. Although semaglutide reduces major adverse cardiovascular events (MACE), the consistency and exact magnitude of its standalone effect on CVD across various patient phenotypes require comprehensive evaluation. This meta-analysis systemati...

G. Marino, S. Aquilani, S. D. Di Fusco et al. · 0 citations
Review Nov 2026

[Ten questions about cardiogenetics].

This review aims to provide clinicians with an updated and pragmatic guide to the use of genetic testing in inherited cardiovascular diseases, and addresses when genetic testing should be requested in cardiomyopathies and channelopathies, which genes should be tested across different conditions, and how genetic results...

F. Fortuni, A. Matteucci, F. Angelini et al. · 0 citations
Review Nov 2026

[Multimodality imaging in heart failure: phenotyping and clinical decision-making].

Heart failure (HF) is a global health priority traditionally managed based on ejection fraction (EF). However, EF is now recognized as insufficient to represent the pathophysiological complexity and clinical heterogeneity of the syndrome. Modern diagnostics have shifted toward multimodality imaging, acting as an integr...

F. Musella, S. Carigi, Denitza Tinti et al. · 0 citations
Review Open access Oct 2026

Cardiometabolic Substrate Modification in Atrial Fibrillation: Obesity and Epicardial Adipose Tissue in the Era of Incretin-Based Therapies and Catheter Ablation

Atrial fibrillation (AF) is increasingly understood as the electrical expression of a systemic and atrial cardiometabolic disease rather than an isolated disorder of pulmonary-vein triggers. Obesity, insulin resistance, hypertension, sleep-disordered breathing, heart failure with preserved ejection fraction, and viscer...

A. Matteucci, M. Bonanni, Luca Sgarra et al. · 0 citations
Review Open access Oct 2026

Blood Pressure-Lowering Effects of Finerenone: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Background: Optimal blood pressure (BP) control remains elusive for millions of patients worldwide, often leading to resistant or secondary hypertension. Overactivation of the mineralocorticoid receptor (MR) drives this systemic pathology. While steroidal mineralocorticoid receptor antagonists (MRAs) are effective, the...

G. Marino, S. D. Di Fusco, E. Graziano et al. · 0 citations
Review Sep 2026

Safety and tolerability of nonstatin LDL-cholesterol-lowering therapies: A systematic review and pairwise meta-analysis of randomized controlled trials.

BACKGROUND Nonstatin low-density lipoprotein (LDL)-cholesterol-lowering therapies are increasingly used in secondary prevention, familial hypercholesterolemia, and statin-intolerant patients, but adverse-event reporting is heterogeneous, and harmonized safety evidence remains limited. OBJECTIVE To evaluate the tolera...

A. Matteucci, M. Bonanni, S. D. Di Fusco et al. · 0 citations
Sep 2026

Contemporary invasive management and in-hospital outcomes of acute myocardial infarction in patients with active or prior cancer: insights from the EYESHOT-2 registry.

Cancer status was not significantly associated with non-performance of PCI after multivariable adjustment in either STEMI or NSTEMI, and mortality and bleeding comparisons were unadjusted and limited by small cancer subgroups and few events.

Alessandra Greco, I. Bisceglia, M. Canale et al. · 0 citations
Review Open access Sep 2026

Wearable Cardioverter-Defibrillator in Patients at Transient Risk of Sudden Cardiac Death: State of the Art and Contemporary Clinical Evidence

Overall, current evidence supports the technical efficacy of the WCD for terminating sustained ventricular tachyarrhythmias, but observational shock rates do not establish a population-level survival benefit.

A. Matteucci, M. Bonanni, M. Mariani et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.